# RISK: __Lack of effective pharmaceutical response__ (PBN__Risk_1602)

## Property: has_RiskGBN

* [No](PBN__RiskGBN_0)

## Property: has_RiskName

Delayed response and increased mortality rates

## Property: has_RiskDescription

Ineffective vaccines and long development time for new vaccines and antibiotics

## Property: has_RiskTechnology

* [vaccine development technology](PBN__Technology_917)
* [drug resistance surveillance technology](PBN__Technology_918)

## Property: has_RiskType

* [technological](PBN__RiskType_5)

## Property: has_RiskSubject

* [general population](PBN__Stakeholder_9)
* [healthcare systems](PBN__Stakeholder_193)

## Property: has_RiskMitigation

* [Improve surveillance for drug resistance, invest in vaccine development infrastructure](PBN__RiskMitigation_2137)

## Property: has_RiskSource

* [kumar_role_2021](PBN__Article_140)

## Property: has_RiskOwner

* [none](PBN__Stakeholder_629)

## Property: has_RiskISO_Impact

* [Health and care](PBN__RiskISO_Purpose_0)

## Property: has_RiskISO_Purpose

* [Resilience](PBN__RiskISO_Impact_2)

## Property: has_RiskHealth

* [physical](PBN__RiskHealth_0)

